{"filing":{"accession_number":"0001193125-26-349154","cik":"0001861123","ticker":"EIKN","company_name":"Eikon Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-13","report_date":"2026-08-13","primary_document":"eikn-20260813.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1861123/000119312526349154/eikn-20260813.htm"},"events":[{"id":27584,"run_id":25151,"accession_number":"0001193125-26-349154","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a press release announcing Eikon Therapeutics' second quarter 2026 financial results, including R\u0026D expenses ($75.5M), G\u0026A expenses ($17.9M), net loss ($88.4M), and cash position ($531.2M as of June 30, 2026). The disclosure is furnished under Item 2.02 (Results of Operations and Financial Condition) and includes both financial metrics and clinical/corporate updates. This is a standard quarterly earnings release material to investors assessing the company's financial condition and cash runway.","company_name":"Eikon Therapeutics, Inc.","ticker":"EIKN","filing_date":"2026-08-13","form":"8-K","submitted_at":null,"items":[{"id":29171,"accession_number":"0001193125-26-349154","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a press release announcing Eikon Therapeutics' second quarter 2026 financial results, including R\u0026D expenses ($75.5M), G\u0026A expenses ($17.9M), net loss ($88.4M), and cash position ($531.2M as of June 30, 2026). The disclosure is furnished under Item 2.02 (Results of Operations and Financial Condition) and includes both financial metrics and clinical/corporate updates. This is a standard quarterly earnings release material to investors assessing the company's financial condition and cash runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T03:01:30.800170+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29171,"accession_number":"0001193125-26-349154","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a press release announcing Eikon Therapeutics' second quarter 2026 financial results, including R\u0026D expenses ($75.5M), G\u0026A expenses ($17.9M), net loss ($88.4M), and cash position ($531.2M as of June 30, 2026). The disclosure is furnished under Item 2.02 (Results of Operations and Financial Condition) and includes both financial metrics and clinical/corporate updates. This is a standard quarterly earnings release material to investors assessing the company's financial condition and cash runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T03:01:30.800170+00:00","company_name":"Eikon Therapeutics, Inc.","ticker":"EIKN","filing_date":"2026-08-13"}]}